PET scan for suspicious prostate spots before biopsy
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether a special PET scan (called POSLUMA) can help find prostate cancer earlier in men who have an MRI showing a suspicious spot (PIRADS 2 or 3) but haven't yet had a biopsy. If you are scheduled for a biopsy, this scan may give your doctor extra information before the procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older
- You have never had a prostate biopsy before
- You had a special MRI of your prostate (called mpMRI) in the last 3 months
- You are scheduled to get a targeted MRI/ultrasound-guided prostate biopsy
- Your MRI showed a PIRADS 2 or 3 lesion (a spot that may or may not be cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to detect prostate cancer when your PSA level is slightly rising after prostate removal surgery. It aims to find cancer early so treatment decisions can be better informed.
This trial tests a special PET/MRI scan that may help doctors see if prostate cancer has spread to nearby lymph nodes before surgery. It could help guide treatment decisions for men with high-risk prostate cancer.
This trial tests whether a new imaging agent (flotufolastat F 18 PET CT) can find prostate cancer better than MRI. If you have a suspicious spot on an MRI, this study may help doctors see if the new scan is more accurate.
This trial tests a new imaging scan that combines a special PET tracer with MRI to help guide a prostate biopsy. The goal is to see if this scan can more accurately find cancer and reduce the need for extra biopsies.
This trial tests a new PET scan (a type of imaging) called Flotufolastat to see if it can better monitor prostate cancer after you receive focal therapy—a treatment that targets only the cancer area rather than the whole prostate. The goal is to help doctors know if the treatment worked and catch any remaining cancer early.
This early-phase study tests a special PET-MRI scan using rhPSMA-73 to better detect prostate cancer areas in men who would otherwise choose active surveillance. It may help doctors see where (and how much) cancer is present before deciding on treatment.
Hear when a new Prostate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.